ArticleBlood2021
Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage.
Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- ABO-Incompatible Platelet Transfusions and Mortality Risk in Patients With Intracranial Hemorrhage.Neurosurgery · 2026Article
- Chemically Defined, Efficient Megakaryocyte Production from Human Pluripotent Stem Cells.Cells · 2025Article
- Major ABO-Incompatible Platelet Transfusions Are Associated With Brain Ischemia After Intracerebral Hemorrhage.Stroke · 2025Article
- Admission Viscoelastic Hemostatic Assay Parameters Predict Poor Long-Term Intracerebral Hemorrhage Outcomes.Neurocritical care · 2025Article
- The Effects of High Particulate Matter Levels on Platelet Recovery in Patients Receiving Prophylactic Platelet Transfusion.Journal of blood medicine · 2025Article
- DoTropical medicine and infectious disease · 2024Article
- Admission viscoelastic hemostatic assay parameters predict poor long-term intracerebral hemorrhage outcomes.Research square · 2024Article
- ABO blood group, ABO mismatched transfusions and leukoreduction of transfusions in hemostatic resuscitation studies.Frontiers in bioengineering and biotechnology · 2024Article
- ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage.PloS one · 2024Article
- Effect of antiplatelet therapy on the incidence, prognosis, and rebleeding of intracerebral hemorrhage.CNS neuroscience & therapeutics · 2023Review
- Associations between ABO non-identical platelet transfusions and patient outcomes-A multicenter retrospective analysis.Transfusion · 2023Article
- Review
- Observational
- Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions.Circulation research · 2022Review
- Essential Role of Rho-Associated Kinase in ABO Immune Complex-Mediated Endothelial Barrier Disruption.Biomedicines · 2021Article
- Rethinking platelet transfusion practices.Blood · 2021Article
- The Effect of Preoperative Antiplatelet Therapy on Early Postoperative Rehemorrhage and Outcomes in Patients With Spontaneous Intracranial Hematoma.Frontiers in aging neuroscience · 2021Article
- Prediction of Hematoma Expansion in Patients With Intracerebral Hemorrhage Using Thromboelastography With Platelet Mapping: A Prospective Observational Study.Frontiers in neurology · 2021Article
- ABO blood groups and galectins: Implications in transfusion medicine and innate immunity.Seminars in immunologyReview
- Impact of dose and storage duration of platelet concentrates on platelet recovery between ABO identical and ABO non-identical random donor platelet transfusions in hemato-oncology patients.Hematology, transfusion and cell therapyArticle
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute platelet transfusion after intracerebral hemorrhage (ICH) given in efforts to reverse antiplatelet medication effects and prevent ongoing bleeding does not appear to improve outcome and may be associated with harm. Although the underlying mechanisms are unclear, the influence of ABO-incompatible platelet transfusions on ICH outcomes has not been investigated. We hypothesized that patients with ICH who receive ABO-incompatible platelet transfusions would have worse platelet recovery (using absolute count increment [ACI]) and neurological outcomes (mortality and poor modified Rankin Scale [mRS 4-6]) than those receiving ABO-compatible transfusions. In a single-center cohort of consecutively admitted patients with ICH, we identified 125 patients receiving acute platelet transfusions, of whom 47 (38%) received an ABO-incompatible transfusion. Using quantile regression, we identified an association of ABO-incompatible platelet transfusion with lower platelet recovery (ACI, 2 × 103cells per μL vs 15 × 103cells per μL; adjusted coefficient β, -19; 95% confidence interval [CI], -35.55 to -4.44; P = .01). ABO-incompatible platelet transfusion was also associated with increased odds of mortality (adjusted odds ratio [OR], 2.59; 95% CI, 1.00-6.73; P = .05) and poor mRS (adjusted OR, 3.61; 95% CI, 0.97-13.42; P = .06); however, these estimates were imprecise. Together, these findings suggest the importance of ABO compatibility for platelet transfusions for ICH, but further investigation into the mechanism(s) underlying these observations is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.